{"name":"Genzyme, a Sanofi Company","slug":"genzyme-a-sanofi-company","ticker":"","exchange":"","domain":"genzymeasanoficompany.com","description":"","hq":"Cambridge","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1100000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Myozyme","genericName":"Myozyme","slug":"myozyme","revenue":1100000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":1100000000,"percentOfTotal":100,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Myozyme","genericName":"Myozyme","slug":"myozyme","indication":"Lysosomal alpha-1,4-glucosidase deficiency - infantile onset","status":"marketed","revenue":1100000000},{"name":"factor concentrates","genericName":"factor concentrates","slug":"factor-concentrates","indication":"Hemophilia A (Factor VIII deficiency)","status":"phase_3"},{"name":"Fabrazyme (agalsidase beta)","genericName":"Fabrazyme (agalsidase beta)","slug":"fabrazyme-agalsidase-beta","indication":"Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease","status":"marketed"},{"name":"Fitusiran (SAR439774)","genericName":"Fitusiran (SAR439774)","slug":"fitusiran-sar439774","indication":"Hemophilia A prophylaxis (including patients with inhibitors)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"cardiovascular","drugs":[{"name":"Enteric coated sevelamer","genericName":"Enteric coated sevelamer","slug":"enteric-coated-sevelamer","indication":"Chronic kidney disease","status":"phase_2"},{"name":"GZ389988","genericName":"GZ389988","slug":"gz389988","indication":"Other","status":"phase_2"},{"name":"GZ402666","genericName":"GZ402666","slug":"gz402666","indication":"Other","status":"phase_1"},{"name":"doxercalciferol capsules, Hectorol® capsules","genericName":"doxercalciferol capsules, Hectorol® capsules","slug":"doxercalciferol-capsules-hectorol-capsules","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis","status":"marketed"},{"name":"ALGLUCOSIDASE ALFA (MYOZYME)","genericName":"ALGLUCOSIDASE ALFA (MYOZYME)","slug":"alglucosidase-alfa-myozyme","indication":"Pompe disease (glycogen storage disease type II)","status":"marketed"},{"name":"Aldurazyme","genericName":"Aldurazyme","slug":"aldurazyme","indication":"Mucopolysaccharidosis, MPS-I","status":"marketed"},{"name":"Alglucosidase alfa (GZ419829)","genericName":"Alglucosidase alfa (GZ419829)","slug":"alglucosidase-alfa-gz419829","indication":"Pompe disease (glycogen storage disease type II)","status":"phase_3"},{"name":"Calcium acetate (PhosLo® )","genericName":"Calcium acetate (PhosLo® )","slug":"calcium-acetate-phoslo","indication":"Hyperphosphatemia in patients with end-stage renal disease on hemodialysis or peritoneal dialysis","status":"phase_3"},{"name":"Calcium-based phosphate binder","genericName":"Calcium-based phosphate binder","slug":"calcium-based-phosphate-binder","indication":"Other","status":"marketed"},{"name":"Ceterizine","genericName":"Ceterizine","slug":"ceterizine","indication":"Other","status":"phase_3"},{"name":"Colesevelam hydrochloride film-coated tablets","genericName":"Colesevelam hydrochloride film-coated tablets","slug":"colesevelam-hydrochloride-film-coated-tablets","indication":"Other","status":"marketed"},{"name":"GC1008","genericName":"GC1008","slug":"gc1008","indication":"Other","status":"phase_2"},{"name":"Genz-644470","genericName":"Genz-644470","slug":"genz-644470","indication":"Other","status":"phase_2"},{"name":"Myozyme® (alglucosidase alfa)","genericName":"Myozyme® (alglucosidase alfa)","slug":"myozyme-alglucosidase-alfa","indication":"Pompe disease (glycogen storage disease type II) in infants and children","status":"marketed"},{"name":"Weight-Based Plerixafor","genericName":"Weight-Based Plerixafor","slug":"weight-based-plerixafor","indication":"Other","status":"marketed"},{"name":"doxercalciferol capsules, Hectorol®","genericName":"doxercalciferol capsules, Hectorol®","slug":"doxercalciferol-capsules-hectorol","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"neuroscience","drugs":[{"name":"Fixed Dose Plerixafor","genericName":"Fixed Dose Plerixafor","slug":"fixed-dose-plerixafor","indication":"Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma","status":"marketed"},{"name":"ILX651","genericName":"ILX651","slug":"ilx651","indication":"Thyroid cancer","status":"phase_2"},{"name":"131I","genericName":"131I","slug":"131i","indication":"Thyroid cancer (radioiodine-avid differentiated thyroid cancer)","status":"phase_2"},{"name":"Alemtuzumab (GZ402673)","genericName":"Alemtuzumab (GZ402673)","slug":"alemtuzumab-gz402673","indication":"Relapsing-remitting multiple sclerosis","status":"marketed"},{"name":"Alemtuzumab plus Fludarabine","genericName":"Alemtuzumab plus Fludarabine","slug":"alemtuzumab-plus-fludarabine","indication":"Chronic lymphocytic leukemia","status":"phase_2"},{"name":"Caprelsa","genericName":"Caprelsa","slug":"caprelsa","indication":"Carcinoma of thyroid","status":"marketed"},{"name":"FluCAM [Fludara + Campath]","genericName":"FluCAM [Fludara + Campath]","slug":"flucam-fludara-campath","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"GZ402665","genericName":"GZ402665","slug":"gz402665","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_2"},{"name":"Generic = Plerixafor","genericName":"Generic = Plerixafor","slug":"generic-plerixafor","indication":"Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma","status":"phase_3"},{"name":"Thyrogen + Radioiodine (131I)","genericName":"Thyrogen + Radioiodine (131I)","slug":"thyrogen-radioiodine-131i","indication":"Thyroid cancer (differentiated thyroid cancer with radioiodine-avid metastases)","status":"phase_3"},{"name":"Vandetanib (SAR390530)","genericName":"Vandetanib (SAR390530)","slug":"vandetanib-sar390530","indication":"Medullary thyroid cancer","status":"phase_3"},{"name":"clofarabine (IV formulation)","genericName":"clofarabine (IV formulation)","slug":"clofarabine-iv-formulation","indication":"Relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and adult patients","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"G-CSF and plerixafor","genericName":"G-CSF and plerixafor","slug":"g-csf-and-plerixafor","indication":"Autologous hematopoietic stem cell mobilization","status":"phase_2"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"AAV2-sFLT01","genericName":"AAV2-sFLT01","slug":"aav2-sflt01","indication":"Age-related macular degeneration","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"BPA prophylaxis","genericName":"BPA prophylaxis","slug":"bpa-prophylaxis","indication":"Prophylaxis of breakthrough polyomavirus-associated nephropathy in immunocompromised patients","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Colesevelam Cholestagel","genericName":"Colesevelam Cholestagel","slug":"colesevelam-cholestagel","indication":"Hypercholesterolemia (approved)","status":"phase_2"}]}],"pipeline":[{"name":"Myozyme","genericName":"Myozyme","slug":"myozyme","phase":"marketed","mechanism":"Biologic","indications":["Lysosomal alpha-1,4-glucosidase deficiency - infantile onset"],"catalyst":""},{"name":"G-CSF and plerixafor","genericName":"G-CSF and plerixafor","slug":"g-csf-and-plerixafor","phase":"phase_2","mechanism":"Stimulates the production of neutrophils by binding to the G-CSF receptor","indications":["Autologous hematopoietic stem cell mobilization"],"catalyst":""},{"name":"Enteric coated sevelamer","genericName":"Enteric coated sevelamer","slug":"enteric-coated-sevelamer","phase":"phase_2","mechanism":"Sevelamer binds to phosphate ions in the gastrointestinal tract, reducing phosphate absorption.","indications":["Chronic kidney disease","Hyperphosphatemia"],"catalyst":""},{"name":"Fixed Dose Plerixafor","genericName":"Fixed Dose Plerixafor","slug":"fixed-dose-plerixafor","phase":"marketed","mechanism":"Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation.","indications":["Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma"],"catalyst":""},{"name":"GZ389988","genericName":"GZ389988","slug":"gz389988","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GZ402666","genericName":"GZ402666","slug":"gz402666","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ILX651","genericName":"ILX651","slug":"ilx651","phase":"phase_2","mechanism":"ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment.","indications":["Thyroid cancer"],"catalyst":""},{"name":"doxercalciferol capsules, Hectorol® capsules","genericName":"doxercalciferol capsules, Hectorol® capsules","slug":"doxercalciferol-capsules-hectorol-capsules","phase":"marketed","mechanism":"Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis","Secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease not on dialysis"],"catalyst":""},{"name":"factor concentrates","genericName":"factor concentrates","slug":"factor-concentrates","phase":"phase_3","mechanism":"Factor concentrates replace or supplement deficient clotting factors to restore hemostatic function in patients with bleeding disorders.","indications":["Hemophilia A (Factor VIII deficiency)","Hemophilia B (Factor IX deficiency)","Other inherited factor deficiencies","Acquired coagulation factor deficiencies"],"catalyst":""},{"name":"131I","genericName":"131I","slug":"131i","phase":"phase_2","mechanism":"Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid tissue and thyroid cancer cells.","indications":["Thyroid cancer (radioiodine-avid differentiated thyroid cancer)","Hyperthyroidism"],"catalyst":""},{"name":"AAV2-sFLT01","genericName":"AAV2-sFLT01","slug":"aav2-sflt01","phase":"phase_1","mechanism":"VEGF inhibitor","indications":["Age-related macular degeneration"],"catalyst":""},{"name":"ALGLUCOSIDASE ALFA (MYOZYME)","genericName":"ALGLUCOSIDASE ALFA (MYOZYME)","slug":"alglucosidase-alfa-myozyme","phase":"marketed","mechanism":"Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes, restoring normal cellular function in Pompe disease.","indications":["Pompe disease (glycogen storage disease type II)","Infantile-onset Pompe disease","Late-onset Pompe disease"],"catalyst":""},{"name":"Aldurazyme","genericName":"Aldurazyme","slug":"aldurazyme","phase":"marketed","mechanism":"Biologic","indications":["Mucopolysaccharidosis, MPS-I"],"catalyst":""},{"name":"Alemtuzumab (GZ402673)","genericName":"Alemtuzumab (GZ402673)","slug":"alemtuzumab-gz402673","phase":"marketed","mechanism":"Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion.","indications":["Relapsing-remitting multiple sclerosis","Chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"Alemtuzumab plus Fludarabine","genericName":"Alemtuzumab plus Fludarabine","slug":"alemtuzumab-plus-fludarabine","phase":"phase_2","mechanism":"Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis.","indications":["Chronic lymphocytic leukemia"],"catalyst":""},{"name":"Alglucosidase alfa (GZ419829)","genericName":"Alglucosidase alfa (GZ419829)","slug":"alglucosidase-alfa-gz419829","phase":"phase_3","mechanism":"Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes in Pompe disease.","indications":["Pompe disease (glycogen storage disease type II)"],"catalyst":""},{"name":"BPA prophylaxis","genericName":"BPA prophylaxis","slug":"bpa-prophylaxis","phase":"phase_3","mechanism":"BPA prophylaxis prevents breakthrough polyomavirus-associated nephropathy (BPA) in immunocompromised patients, likely through antiviral or immunomodulatory mechanisms.","indications":["Prophylaxis of breakthrough polyomavirus-associated nephropathy in immunocompromised patients"],"catalyst":""},{"name":"Calcium acetate (PhosLo® )","genericName":"Calcium acetate (PhosLo® )","slug":"calcium-acetate-phoslo","phase":"phase_3","mechanism":"Calcium acetate binds to dietary phosphate in the gastrointestinal tract to reduce serum phosphate levels in patients with hyperphosphatemia.","indications":["Hyperphosphatemia in patients with end-stage renal disease on hemodialysis or peritoneal dialysis"],"catalyst":""},{"name":"Calcium-based phosphate binder","genericName":"Calcium-based phosphate binder","slug":"calcium-based-phosphate-binder","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Caprelsa","genericName":"Caprelsa","slug":"caprelsa","phase":"marketed","mechanism":"AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial","indications":["Carcinoma of thyroid","Medullary thyroid carcinoma"],"catalyst":""},{"name":"Ceterizine","genericName":"Ceterizine","slug":"ceterizine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Colesevelam Cholestagel","genericName":"Colesevelam Cholestagel","slug":"colesevelam-cholestagel","phase":"phase_2","mechanism":"Colesevelam is a bile acid sequestrant that binds bile acids in the intestine to prevent their reabsorption, thereby lowering LDL cholesterol and improving glycemic control.","indications":["Hypercholesterolemia (approved)","Type 2 diabetes mellitus (Phase 2 development)"],"catalyst":""},{"name":"Colesevelam hydrochloride film-coated tablets","genericName":"Colesevelam hydrochloride film-coated tablets","slug":"colesevelam-hydrochloride-film-coated-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fabrazyme (agalsidase beta)","genericName":"Fabrazyme (agalsidase beta)","slug":"fabrazyme-agalsidase-beta","phase":"marketed","mechanism":"α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)","indications":["Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease"],"catalyst":""},{"name":"Fitusiran (SAR439774)","genericName":"Fitusiran (SAR439774)","slug":"fitusiran-sar439774","phase":"marketed","mechanism":"Fitusiran is an RNA interference (RNAi) therapeutic that silences antithrombin (AT) messenger RNA to reduce antithrombin levels and enhance the intrinsic coagulation pathway, thereby increasing thrombin generation in patients with hemophilia.","indications":["Hemophilia A prophylaxis (including patients with inhibitors)","Hemophilia B prophylaxis (including patients with inhibitors)"],"catalyst":""},{"name":"FluCAM [Fludara + Campath]","genericName":"FluCAM [Fludara + Campath]","slug":"flucam-fludara-campath","phase":"phase_3","mechanism":"FluCAM combines a purine nucleoside analog that inhibits DNA synthesis with a monoclonal antibody that depletes lymphocytes, providing dual immunosuppressive and cytotoxic activity.","indications":["Chronic lymphocytic leukemia (CLL)","B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"GC1008","genericName":"GC1008","slug":"gc1008","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GZ402665","genericName":"GZ402665","slug":"gz402665","phase":"phase_2","mechanism":"GZ402665 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","indications":["Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"Generic = Plerixafor","genericName":"Generic = Plerixafor","slug":"generic-plerixafor","phase":"phase_3","mechanism":"Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood.","indications":["Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma"],"catalyst":""},{"name":"Genz-644470","genericName":"Genz-644470","slug":"genz-644470","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Myozyme® (alglucosidase alfa)","genericName":"Myozyme® (alglucosidase alfa)","slug":"myozyme-alglucosidase-alfa","phase":"marketed","mechanism":"Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes, restoring normal cellular function in Pompe disease.","indications":["Pompe disease (glycogen storage disease type II) in infants and children","Pompe disease in adults"],"catalyst":""},{"name":"Thyrogen + Radioiodine (131I)","genericName":"Thyrogen + Radioiodine (131I)","slug":"thyrogen-radioiodine-131i","phase":"phase_3","mechanism":"Thyrogen (recombinant human TSH) stimulates thyroid tissue to take up radioiodine (131I), enabling targeted destruction of thyroid cancer cells and metastases.","indications":["Thyroid cancer (differentiated thyroid cancer with radioiodine-avid metastases)","Thyroid remnant ablation in thyroid cancer patients"],"catalyst":""},{"name":"Vandetanib (SAR390530)","genericName":"Vandetanib (SAR390530)","slug":"vandetanib-sar390530","phase":"phase_3","mechanism":"Vandetanib is a tyrosine kinase inhibitor that targets RET, VEGFR2, and EGFR.","indications":["Medullary thyroid cancer"],"catalyst":""},{"name":"Weight-Based Plerixafor","genericName":"Weight-Based Plerixafor","slug":"weight-based-plerixafor","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"clofarabine (IV formulation)","genericName":"clofarabine (IV formulation)","slug":"clofarabine-iv-formulation","phase":"phase_3","mechanism":"Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to cell death in rapidly dividing cancer cells.","indications":["Relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and adult patients","Relapsed or refractory acute myeloid leukemia (AML)"],"catalyst":""},{"name":"doxercalciferol capsules, Hectorol®","genericName":"doxercalciferol capsules, Hectorol®","slug":"doxercalciferol-capsules-hectorol","phase":"marketed","mechanism":"Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone (PTH) secretion.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis","Secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease not on dialysis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9pbGxhSERtOWVub01JQzl0QVdXZUdycDJPQjlsT3ctZFlDNzZqUzQ5QU1IbFNOM1dPS1k3Y1FDYnZxS2NzZldpSkhpYV9DWWl3ZXRDelNSWXNjLW1FMkdoVlFLMmVXZFE1R1MwNW9OVUNydjFlaUZCaGNacmY?oc=5","date":"2026-02-24","type":"earnings","source":"statista.com","summary":"Revenue of Sanofi from 2006 to 2025 - statista.com","headline":"Revenue of Sanofi from 2006 to 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNQ1ZoY2ozQjRwU01MZkw3ZVZkd29KM2lrRThsY3h4bzBJWTllbzduSExva1pxUVJyMk1Fenh0SXRwRVNDdXIxMFI5X2hLTDZwTGh4aENlVmpOVVRtVWJ3R3ZfUHRORHB6MnZKaFYwSWw1SUhOeU1ybGtTa2IzdDJYRFp3dllDWktrcElaV1dkdFRNZw?oc=5","date":"2026-02-02","type":"trial","source":"BioPharma Dive","summary":"Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials - BioPharma Dive","headline":"Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNRzVyM3JucU4xX1ZtTHVsWFY2dm5iOGY1VlFkWkt4c25zUTVQMVpwQ3ZieExqOG95OE5kRlNsZHFKV0lpNmdON05HdlZvYTZZMHlzVlVnbG5JY0tYbGM5NFJ2QzNxQlRZOGQ2bUVuemZxZ3l5NGgtMGpoWXp6SmRlbFJBZm10c29reV9jME9vdEJaX041RXp6VjJQUnRrcXF1cTJ6Mkh4STFUVnhpc0poeFBhZThrNlFSaGkwWkY1aENVSDY4R3c4eGJPbld4QkdJRGYwSGNnQUxsSW1OWVJv?oc=5","date":"2026-02-02","type":"pipeline","source":"reuters.com","summary":"UK industry body says Sanofi in breach over RSV therapy claims against Pfizer - reuters.com","headline":"UK industry body says Sanofi in breach over RSV therapy claims against Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNc2JrTHh6TVhfeElCdmlBWWpfaU8wODJMT2hqX0xXOUtkd3RFbk0wMWpBOXpNUVVmYUs3RndDb0V4UnBnZ1o2ekZhUmkzVGs1QnBhSlRGaldLQW5ja0taUURMY2ZPWlM1OE9BY3RsNFdscHE0VGF6eG5QTHFCRUp1bFJWTWRpV2prMjF3ZThrOFhpa0tYTlAyVG9BbENaSjliTW5UWHlzU3hPZENRTFNFZ3kxWjNtRVJadXV1ZWY0UG1wVWxlS2dsLTdlMA?oc=5","date":"2025-08-06","type":"pipeline","source":"reuters.com","summary":"US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies - reuters.com","headline":"US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNWm1vUU83RHpuUGJHSkZJbmxYRW53UWh0ak0yWE9XcXlHSEZpaXJBRGhZRWhERDROUVpCY2FzVUUtZG01dDUzbF95MEV2cDRmZzYxM3IweFRWU3ZXV0staVJJcFloeTJWWTNOLTRrQlNmdWJ5ZW1VNFdKQ0VueEtTcG1zTXZfT09pUVNnVTBuSEJjbEZWUHNuZDAyZXJodFJQSl9hSTZIVk5UdmZVUkFRYlNpbjRVcUY1U2xaVA?oc=5","date":"2025-07-16","type":"pipeline","source":"Fierce Pharma","summary":"Thermo Fisher bolsters US fill-finish capacity with Sanofi plant purchase - Fierce Pharma","headline":"Thermo Fisher bolsters US fill-finish capacity with Sanofi plant purchase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPNDM4Z0NhWi16UmJNbHRIQVplSG9tYVE2NWM2ZGZzUHpYQ0daRkhoWWE2WV9nLWdmUUpSUWpfUmdPSFN4aHhNWDNBTkZtMi0tZ0pObkpJamJadEZnMTl2LXZCQ3AtQnBwUUFxVDEtb3NXYVNlUTliMENwLWd1eDNJS0xncnZ4V2txdUhkMHNDTmtGR3JhQ05XWmxHVmFyUWNPZk54S1NmUVNuZ3hqT2NSVg?oc=5","date":"2025-01-21","type":"regulatory","source":"Fierce Pharma","summary":"Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs - Fierce Pharma","headline":"Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFB4bWUtMnY2Vk8yYnNiWW0zR01vMmdlVi1HbGRQUDdyU29WZ1o4TUNCem1IZ0xGbnNzRUFjUk0xVkRjUTJ1S2hGN0dINE5KQlNUdmJLS3RGelQxaHNoNGVKWmtFNURTX3dpRnZsdEFteF9pQQ?oc=5","date":"2023-02-23","type":"pipeline","source":"Labiotech.eu","summary":"Sanofi-Genzyme: Still successful 5 years after the acquisition? - Labiotech.eu","headline":"Sanofi-Genzyme: Still successful 5 years after the acquisition?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9JS1lTc2JFWUk4SDBHMGd4M3U2bGlRTl9uS3ZVZ1kwbnhld0o5aGRPaHFWUHY5emRGeGJCN2dRdW1TaHNVRUwyLTlMZ2ZNMl9jcGQwbnRJeEhxaDZQcXpDY0JzTW1nWHZMeWRoUTlFcmE?oc=5","date":"2022-02-03","type":"deal","source":"statnews.com","summary":"Eleven years after buying Genzyme, Sanofi officially ditches subsidiary’s storied name - statnews.com","headline":"Eleven years after buying Genzyme, Sanofi officially ditches subsidiary’s storied name","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxObnJjOXE3ZmNWa05zSW9DWExVMG11WWd3UTBQVUJyY2VNWUxwWUNxR3RiUWhQbmN3X1ppSl93XzlqTzBzRVVhekdVOEV6b3NfUTJGQXJRa2VoQzRFOHg4MTRwRmpvTEtudEVmdGxaTmpLVEw4QlBBSmFoOU42UmZNMERwci0zX2JPb3k4TjZVUFVHM0F1YkVHNWs0ZHQxcVBITmwwU1pYNXV2enF3VDVlN2tiaTk?oc=5","date":"2021-06-14","type":"deal","source":"Fierce Biotech","summary":"Symptom checking platform developer Ada Health inks partnerships with Sanofi, Takeda, Alnylam - Fierce Biotech","headline":"Symptom checking platform developer Ada Health inks partnerships with Sanofi, Takeda, Alnylam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOY2NzdkQwS3UtaGR1TFdKTU5WbmlXcUpOQzhVM1lGWmpZcC1GLU1YR1NVbjctWmQ3UTN0VUFsTnRZT0xDNDJ5Q0ZRWGNlWi1IcV95clk0Y3ByUm1SckFLLUg0YS1KNGFqS25Hb2tXMFhuQjByeTdpbmpFYVZmX3N3OFZ5cWZBR3Fmcy1fNWl30gHCAUFVX3lxTFA4OERPYlNmamxXWXoyNzB0dlFJQkVadjdWVzNlazl2UHltUllLeHczNDZNX2I2LVF1cGRiYWZXWExiT2hfRjkzaWdWemZBbFlDYXB4OEZRMjEzQlJGNGVfaDZuYWp1YWpIaXNSRmN3eTFKcThUSWw2ckZuZ3A5NTFCSDlBa2xwZDhEazZ3dXJYUk9POFA0dFRlS3l2bE9mbHNacXl0NlNlZjdhcXF3am5wb08yZkZHbU1obEtKS1lsTkV3?oc=5","date":"2021-03-16","type":"pipeline","source":"Cedarville University","summary":"Pharmacy Student Earns First Industry Fellowship - Cedarville University","headline":"Pharmacy Student Earns First Industry Fellowship","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBYYjNDU2N4TlhNalZiRldhbFlSQmRwT3R1d2hZMUtTZXFneGF3N05rU1FXSEhod1FtYzl5d0NJVjI0eU0yeUZ3RU90QkMzREl4dHdJZmtSZDJwaGpHTGw1UVlHalI?oc=5","date":"2013-02-25","type":"pipeline","source":"pharmaphorum","summary":"A history of Sanofi - pharmaphorum","headline":"A history of Sanofi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNMU44ZndLMEtDZFZRcl9zdFlQc2x3cUJCb2tycHB1d1Vaa2I3V2IxaERJMWduMWRmS2hRdU83M3ZWQ25NczVnaWVaZ1RkbHdSQWxVT1ZLNjFHVVFfMEFCbHRZcFBCNnpiamVNUThnd2hrLW5PRTEwVDZlZVdXZVI0U3JCTU90NWd4N25HM0hCQ3dpZWxXTmduMkNJMjd2dVZvcDJkZmU2Z3lHT182eUVETlRfRTNjZw?oc=5","date":"2011-04-08","type":"pipeline","source":"European Pharmaceutical Review","summary":"Sanofi-Aventis completes acquisition of Genzyme Corporation - European Pharmaceutical Review","headline":"Sanofi-Aventis completes acquisition of Genzyme Corporation","sentiment":"neutral"}],"patents":[],"drugCount":36,"phaseCounts":{"marketed":14,"phase_2":10,"phase_1":2,"phase_3":10},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}